.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a median consequence of 11 months, patients along with metastatic gastrointestinal cysts who obtained biomarker-matched treatments based on distributing tumor DNA profiling revealed a more significant professional advantage than those getting unmatched treatment.